The DOI matches its Crossref record.
Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties.
Abstract
Amphotericin B (AmB) has been in clinical use for more than 30 yr but has remained the most effective drug for treatment of serious fungal infections. Its use has increased in recent years, as the result of increases in aggressive intensive care support and increased numbers of immunocompromised patients. Nephrotoxic manifestations are common, and this is the major factor limiting the clinical use of the drug. A number of recent studies have contributed to a better understanding of the mechanism by which AmB exerts its nephrotoxic effect. AmB alters cell membrane permeability and probably as a consequence alters tubular and vascular smooth muscle cell function, leading to various tubular transport defects and vasoconstriction. Decreased RBF appears to play a major role in AmB-induced reduction GFR, and recurrent ischemia may be the basis of permanent structural nephrotoxic effects. Salt loading is the only measure proven by controlled prospective study to ameliorate AmB nephrotoxicity in humans. Liposomal AmB and the formulation of an emulsion of AmB in lipid may provide a protective effect based on altering the affinity of AmB for mammalian cell membranes, while preserving high efficacy against fungal cells. However, further studies are needed to evaluate the efficacy and safety of these new AmB formulations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Amphotericin B formulations: a comparative review of efficacy and toxicity
Hamill, R. J. (2013) · Drugs · doi:10.1007/s40265-013-0069-4 · Cited by 807
Groll, A. H., Piscitelli, S. C., & Walsh, T. J. (1998) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60129-5 · Cited by 377
An overview of drug-induced acute kidney injury
Pannu, N., & Nadim, M. K. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e318168e375 · Cited by 352
Heil, G., Hoelzer, D., Sanz, M. A., Lechner, K., Liu Yin, J. A., Papa, G., Noens, L., Szer, J., Ganser, A., O'Brien, C., et al. (1997) · Blood · doi:10.1182/blood.v90.12.4710 · Cited by 332
Lemke, A., Kiderlen, A. F., & Kayser, O. (2005) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-005-1955-9 · Cited by 305
Amphotericin B-induced nephrotoxicity: a review.
Fanos, V., & Cataldi, L. (2000) · Journal of Chemotherapy · doi:10.1179/joc.2000.12.6.463 · Cited by 259
Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis
Santangelo, R., Paderu, P., Delmas, G., Chen, Z.-W., Mannino, R., Zarif, L., & Perlin, D. S. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2356-2360.2000 · Cited by 150
The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy
Wiederhold, N. P., & Lewis, R. E. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.8.1313 · Cited by 144
Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis
Alvarez, C. A., Wiederhold, N. P., McConville, J. T., Peters, J. I., Najvar, L. K., Graybill, J. R., Coalson, J. J., Talbert, R. L., Burgess, D. S., Bocanegra, R., et al. (2007) · Journal of Infection · doi:10.1016/j.jinf.2007.01.014 · Cited by 43
Metadata
- Authors
- Sawaya, B. P., Briggs, J. P., & Schnermann, J.
- Venue
- Journal of the American Society of Nephrology
- Published
- 1995-08
- Volume
- 6
- Issue
- 2
- Pages
- 154-164
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2100485134
- Cited by
- 201
- References
- 0
- FWCI
- 4.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.